Is Bioventus Inc. (BVS) a good stock to buy?
Two or more of our tested checks point the wrong way. When the survival check is one of them, no price makes that acceptable.
What each rating means, in numbers
Can it survive? — Risky. Safer than 19% of the companies we cover, judged on the warning signs that came before companies that really did fail.
Cash it pays you — Low. For every $100 of share price, the business threw off about $3.2 of spare cash a year, averaged over the last three years. Higher is better: the cheap fifth on this measure ran about 7.7 points a year ahead of the dear fifth, 2011 to 2025.
Business quality — Strong. Passes 8 of the 9 health checks we can measure — things like making a profit, turning it into cash, and not piling on debt. Across 131,000 company-quarters the weakest scorers went on to fail at 5.4% against 1.4% for the strongest, in every era and all twelve sectors.
How wild is the price? — Wild. The share price swings about 54% in a typical year, which puts it in the above average. Out of every 100 companies that swung like this, about 3.7 went bankrupt within the year. Across the three periods we tested that ran from 0.9% to 5.7%.
What "tested" means here, and why there is no score out of 100
Tested means the read was measured against what actually happened afterwards, on a history that keeps the companies that were later delisted, using only figures that had been filed on the day they are used. Survival was ranked on companies that really did fail. What an owner keeps was tested across the universe from 2011 to 2025.
The full record of everything we have tested is on the research pages.
Which benchmark. Over the period we tested, the median listed company returned +5.8% a year while the S&P 500 returned about +13.9% — the index is weighted by size and was carried by a handful of enormous winners. So "beats the index" and "beats the other companies you could have bought" are different questions. Where a read says it picks better companies, it means the second one. None of these gets you an index fund's return, and we would rather say that than imply otherwise.
The quality read is the strongest thing we have tested: 131,000 company-quarters across 5,300 companies, where the weakest scorers went on to fail at 5.4% against 1.4% for the strongest, holding in every era and all twelve sectors. It still says less likely to break, not likely to beat the market — every band in that study lost to the index at the median, because the median listed company does.
Each read is shown on its own rather than merged into a single score, so you can see which part is strong and which is weak instead of taking an average on trust.
▾ What goes into the smart-money reading
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend, DCF applicability). It excludes the Altman Z score, whose retained-earnings input this filer does not report separately. See the Financial Health section for the full balance-sheet read.
Chance the S&P 500 falls 10% or more in the next three months.
Counted from every day since 2006. Says nothing about BVS — see the board for how it is measured.
📍 Where to start on this page, and what to look at first
How to read BVS
A profitable, cash-generating business — our discounted-cash-flow estimate is the primary lens, cross-checked against what growth the price implies and against peers.
-
1
The verdict + intrinsic value (our DCF) ↓
Our estimate of what a share is worth, versus today's price.
-
2
Reverse-DCF + the interactive calculator ↓
See the growth the price assumes, then flex every assumption yourself to pressure-test it.
-
3
Football field + peers ↓
A cross-check across methods and against comparable companies.
Is Bioventus Inc. (BVS) overvalued?
Macro: Neutral / mid-cycleYes, by our measure: the price is about 53% above what we think the business is worth.
BVS trades at $13.53 vs an estimated
intrinsic value
of $8.83
— a +53.3% premium to model IV.
Today's price is consistent with BVS's owner-earnings free cash flow per share growing about 14.6% per year 5-YR · SCENARIO PATH over the next 5 years (the
price-implied growth rate).
Our DCF projects
modeled growth
of 9.2% per year based on history + sector defaults
(analyst consensus estimates not yet integrated).
TESTED · OURS HAS BEEN CLOSER
When we and the market have disagreed about growth, our number has been the closer one — a median miss of 4.8 points a year against the market's 8.3, measured on 3,279 past filings. That does not make a large gap a sell signal: we tested that too, and companies where the market expected far more than we did went on to return within 1.5 points of everything else. Treat the gap as a description of what the price assumes, not as a prediction. How this was tested →
Note: this is a 5-year, per-share view. The Reverse-DCF section below asks the same question over the same five years on a free-cash-flowFree Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → basis, as a single flat rate — so its number is close but not identical.
▾ Exactly how this 5-year figure is computed
Current price: $13.53 (live)
Discount rate: 9.5%; terminal growth: 3.0%
Forecast: 5 years explicit growth, then a linear fade to terminal; end-of-period cash flows discounted to today
Growth path: the model's scenario-weighted path (conservative 40% / base 35% / optimistic 25% — assumed weights, not measured probabilities) — see the "Three Scenarios, Weighted" table below for the three IVs
Method: solve for the constant 5-year per-share growth rate that, run through this same structure, makes the intrinsic value equal today's price. (The figure below solves the same five years as a single flat rate with no scenario weighting — hence a slightly different number.)
Not investment advice. The model can be wrong. Verify the assumptions in the sections below and consider consulting a licensed advisor for significant decisions.
What return would BVS pay as a bond?
Treat the share as a bond: the "coupon" is the cash an owner could take out this year, and unlike a real bond that coupon can grow. Fix today's price and a conservative growth path, and the only unknown left is the return. That number is comparable across every kind of company — which is the point.
Plainly: at $13.53, BVS pays a 3.2% owner-earnings coupon today. If that coupon grows 9.2% a year for five years and then settles toward 2.5%, and a buyer in year 10 pays 15× that year's owner earnings, the whole trade returns about 4.5% a year — 0.7 points less than a Treasury with none of the business risk. By year 5 the coupon on today's price would be 4.9% (the "yield on cost" Buffett talks about). Our DCF demanded 9.5% for a business this risky; this read falls short of that bar, which is the same conclusion the verdict above reaches by a different route.
Who owns BVS, and how it moves
From the SEC's own filings: every fund manager over $100M reports its holdings each quarter, and every officer and director reports theirs. Each point is what was public at the time.
157 institutions reported holding it at the latest quarter-end.
Riskier than 81% of the stocks we cover
What this rating means, and what it does not
What this rank is — Risky. Riskier than 81% of the companies we cover. Out of every 100 companies ranked here, about 0.8% went bankrupt within the year, against 0.6% for the average company we cover. The rank comes from a model trained on every US filing since 2012, including 823 companies that really did fail, and scored each year by a version that had not seen that year.
What it is not — Not a trade. We tested shorting these names and buying puts, spreads, straddles and condors on them at real option prices, 2010-2025. Every version lost money: the market already prices the distress and the survivors squeeze. A high rank is a reason to read the filings and to size for a total loss, not a reason to bet against the company. A low rank says the balance sheet is calm, not that the price is sensible.
▾ The numbers, the logic, and why not to trade on it
The logic. A model trained on every US filing since 2012 — including 823 companies that went bankrupt or stopped trading under a dollar — ranks each covered stock by its chance of failing in the next year, from its latest filing, price history and credit conditions. The rank is a position among peers; the table is a count of what happened to stocks in each position, scored each year by a model that had not seen that year.
| Rank band | went bankrupt within 12 months | fell 80% or more (or failed) within 12 months | fell 50% or more (or failed) within 6 months |
|---|---|---|---|
| All covered stocks (average) | 0.59% | 4.21% | 8.51% |
| Healthcare (sector average) | 0.94% | 9.47% | 17.69% |
| riskiest 1% | 16.4% | 33.0% | 45.5% |
| next 2% (97-99) | 5.9% | 24.9% | 38.2% |
| next 2% (95-97) | 3.4% | 21.2% | 33.8% |
| next 5% (90-95) | 1.6% | 15.1% | 27.3% |
| next 15% (75-90) ← this stock | 0.8% | 8.5% | 17.8% |
| next 25% (50-75) | 0.2% | 2.7% | 6.2% |
| safest half | <0.1% | 0.5% | 2.1% |
Why not to trade on it. We tested shorting these names and buying puts, spreads, straddles and condors on them at real option prices, 2010–2025: every version lost money. The market already prices the distress, and the survivors squeeze. Use a high rank to read the filings and to size for a total loss — not to bet against the company. A low rank says the balance sheet is calm, not that the price is sensible.
Scored from the most recent SEC filing we had (dated 2026-05-07), which can be a quarterly report newer than the yearly figures used elsewhere on this page; scores last updated 2026-09-18. Within Healthcare: rank 71 of 100. Rough one-year odds for this stock alone: bankruptcy 0.4%, an 80% fall 1.7% (the model overstates the middle of the range). On the same data, the Altman Z score caught 26% of bankruptcies in its riskiest 5%; this rank caught 59%.
▾ The logic, and why not to buy on it
The logic. Trained on 2,900 acquisitions since 2012, the model leans on size (small), age, retained earnings, asset growth, volatility and how many deals the sector has just seen. Announcement = the day the stock jumped, not the day the paperwork was filed.
| top 1% | 15.4% acquired within a year |
| next 2% (97-99) | 10.3% acquired within a year |
| next 2% (95-97) | 9.0% acquired within a year |
| next 5% (90-95) ← this stock | 7.3% acquired within a year |
| next 15% (75-90) | 6.4% acquired within a year |
| next 25% (50-75) | 4.8% acquired within a year |
| bottom half | 3.0% acquired within a year |
Why not to buy on it. A takeover paid a median +22% on the day — but even in the top band about 6 in 7 companies are not bought, and those lag. Buying the whole top list returned what the S&P 500 did (2012–2023), and adding "cheap" or "beaten-down" filters did not change that. Read it as context for a thesis you already have, never as the thesis.
What growth must the market believe? Reverse DCF — Instead of asking "what is this stock worth?", asks "what growth rate is the current market price already assuming?"
Why it matters: It crystallizes the bull thesis as a single number you can argue with. If the market expects 40% growth for 10 years and you do not believe that, the stock is overvalued.
Reference: 10–15% = sustainable for strong companies · 20–25% = exceptional · 30%+ = historically very rare
Traditional DCF asks "what is this stock worth?" Reverse DCF flips it: it treats today's price as correct and solves for the growth rate that justifies it. In plain terms — if our model is right about everything else, the company's cash flow would have to grow (or shrink) by this much every year for the next 5 years for today's price to make sense. If that required growth looks unrealistic, the price is stretched; if it looks easy to beat, the price may be cheap.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → must grow at:
▾ Exactly how this 5-year figure is computed
Forecast length: 5 years at the solved rate, then a linear fade to terminal growth over years 6-10 — the same shape the DCF above uses
Terminal growth after the fade: 3.0%
Discount rate: 9.5% (the rate the model used)
Price used: $13.53 — the live price shown on this page (not frozen)
Method: solve for the constant annual growth rate that makes the discounted 10-year FCF stream + terminal value equal today's price.
An above-average expectation for five years. Achievable for a genuinely strong business that executes well.
For reference: Demanding — relatively few large companies sustain this pace of cash-flow growth for a full decade.
▾ How we computed this · Reality check thresholds · Assumptions
- Starting FCF/share: $0.43 (trailing 3-year average)
- Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation →: 9.5% — standard 8-12%; 9-10% matches S&P 500 historical return - Terminal Growth RateTerminal Growth Rate — The growth rate we assume the company holds forever, after the explicit 10-year forecast period ends.
Why it matters: It anchors the long-tail value. Cannot mathematically exceed long-term GDP growth or the company eventually becomes larger than the global economy.
Reference: 2–3% (matches long-term US GDP growth) · Above 4% is mathematically problematic
Full explanation →: 3.0% — matches long-term GDP growth - Forecast horizon: 10 years explicit + terminal perpetuity
| ≤ 0% | Priced for decline — likely undervalued OR dying business |
| 5-12% | Reasonable; sustainable for quality businesses |
| 12-18% | Demanding — strong execution required |
| 18-25% | Exceptional — few companies sustain for a decade |
| 25-35% | Heroic — historically very rare |
| 35%+ | Borderline impossible at scale |
Sustaining 30%+ cash-flow growth for a full decade at scale is exceedingly rare — the bar is brutally high.
Use the interactive calculator below to change the discount rate, growth and terminal-growth assumptions and watch the value move.
What this rating means
What the rating says — Methods disagree. Methods disagree: the price is ABOVE 1 of 3 method ranges while inside the rest — assumption-sensitive, not clearly fair.
What it does not say — Not a forecast. This shows where today's price sits against several different ways of valuing the business. Where the methods disagree, the spread itself is the useful part - it tells you how much the answer depends on which one you trust.
Football field: where does the price sit?
Different valuation methods produce different fair-value ranges depending on assumptions. Plotting them together lets you see at a glance whether the current price is reasonable across approaches, or only one specific lens.
Industry multiples sourced from: broad market average (sector unknown). See the Peer Basket section below for the peer comparison and its limited-comparables caveat.
How does BVS stack up against its closest peers?
We take the 7 same- or closely-related-industry companies closest in size to BVS and check what investors are paying for each dollar of their revenue (or profits). If BVS is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
| EV / SalesEV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt). Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices. Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding Full explanation → |
1.7x / 3.7x / 5.0x |
| EV / Gross ProfitEV / Gross Profit — Enterprise value divided by gross profit — the multiple paid for what each dollar of sales contributes after direct costs. Why it matters: More refined than EV/Sales for high-margin businesses (software, marketplaces) where gross margin is the real economic engine. Reference: 8–15x for SaaS · 15–25x for hypergrowth software · >30x demanding Full explanation → |
2.7x / 4.8x / 7.9x |
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 7 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (8)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| SGP | SpyGlass Pharma, Inc. | Medical Devices | $942M | — | — | — | — |
| TNDM | TANDEM DIABETES CARE INC | Medical Devices | $1.1B | 1.4x | 2.7x | — | 15.9% |
| SIBN | SI-BONE, Inc. | Medical Devices | $625M | 3.3x | 4.1x | — | 8.4% |
| PRCT | PROCEPT BioRobotics Corp | Medical Devices | $1.5B | 5.0x | 7.9x | — | 15.5% |
| NPCE | NeuroPace Inc | Medical Devices | $564M | 6.2x | 8.1x | — | 3.1% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Medical Devices | $555M | 1.7x | 2.2x | 19.0x | 5.6% |
| STAA | STAAR SURGICAL CO | Ophthalmic Goods | $993M | 4.1x | 5.4x | — | 0.1% |
| SSII | SS Innovations International, Inc. | Medical Devices ·fallback | $789M | 18.6x | 40.3x | — | 2.4% |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
What these health ratings mean, in numbers
Business quality — Strong. Passes 8 of the 9 health checks we can measure — making a profit, turning it into cash, not piling on debt, not issuing shares. Across 131,000 company-quarters the weakest scorers went on to fail at 5.4% within a year against 1.4% for the strongest, and that held in every era and all twelve sectors. It says "less likely to break", not "likely to beat the market".
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
We can't produce a trustworthy Altman Z here: retained earnings weren't separately reported in our data, so a core input would have to be fabricated. Rather than show a categorical "distress" verdict from an invented number, we mark it unavailable. Judge financial health from the leverage, cash position, and the measurable Piotroski checks instead.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✓ Positive net incomeNet income $22.7M in FY2025.
-
✓ Positive operating cash flowOperating cash flow $74.7M (was $38.8M the prior year).
-
✓ Cash flow backs up reported profitOperating cash flow $74.7M vs net income $22.7M.
-
✓ Return on assets improvingReturn on assets 3.3% vs -5.0% a year ago.
-
✓ Debt load (vs assets)Long-term debt is 40.8% of assets vs 42.3% a year ago ($279.0M of $683.6M assets).
-
✓ Short-term liquidity (current ratio)Current ratio 1.70x vs 1.31x a year ago.
-
✗ Share count (dilution)Share count rose 3.2% (64.5M → 66.6M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
✓ Pricing power (gross margin)Gross margin 68.3% vs 67.7% a year ago.
-
✓ Sales per asset (asset turnover)Asset turnover 0.83x vs 0.79x a year ago.
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
What if you assume different inputs?
Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 9.5%, the figure our model used for BVS. Open Advanced to also change beta, growth and the rate path.
Note: the calculator opens at our published value of $8.83 — it is initialised to the same scenario-weighted result, so the two match exactly on load. The moment you move a slider, the value below becomes a single-path what-if at your assumptions (not the three-scenario weighting), which is why it can differ from the headline once you've touched it.
9.1% — beta-based (CAPM), from this stock's BetaBeta — How much the stock moves when the overall market moves. 1.0 = moves with the market; 1.5 = moves 50% more than the market.
Why it matters: Higher beta = more volatile = should demand higher discount rate. Low beta stocks (utilities, consumer staples) move less.
Reference: Most stocks 0.5–1.5 · Defensives ~0.3 · High-vol tech ~1.5–2.0
Full explanation → of 0.83. The safe Treasury rate plus a premium scaled by how much more (or less) volatile the stock is than the market.
9.5% — sector/quality tier. A simpler hurdle set by industry and business durability: lower for stable, wide-moat companies; higher for speculative or micro-caps.
The headline value and this calculator start at 9.5% — the more conservative sector/quality rate (we use the more conservative sector/quality rate when model applicability is limited or the balance sheet is stretched). Drag the slider to the other rate to see the full range.
+53.3%
At the default assumptions the flat path lands near our published value of $8.83. Move any slider to recompute it with your own.
Move any slider above to recompute this against your own assumptions.
⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Bioventus Inc. is well above the model value, with the price 53.3% above intrinsic valueIntrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation → (a 53.3% premium). The market is paying up for the company's revenue growth of 7.2% per year over four years and its positive operating cash flow. The biggest risk that our model's base assumptions prove too high is the compressing gross margin, which has fallen from 70.3% to 68.3%, indicating potential pressure on profitability despite revenue growth.
As of 4 days ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What's free cash flow / what do these mean?
Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.
Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.
Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.
Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
- Stabilization or improvement in gross margin
- Continued growth in operating cash flow
- Further reduction in long-term debt
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Free cash flow rose to $59.4M.
- Gross margin improved to 68% (+1 pts).
- Swung to a profit of $22.7M (from a loss the prior year).
Nothing was clearly worsening year-over-year.
Roughly flat: Revenue was flat -1% to $568.1M.
Management & Leadership
Mark Leonard Singleton serves as the SVP & CFO. Katrina J Church is the SVP & Chief Compliance Officer, and Anthony D'Adamio is the SVP & General Counsel.
SVP & CFO
SVP & Chief Compliance Officer
What They Make
Bioventus Inc. develops and commercializes orthobiologic products for bone healing, pain management, and restorative therapies. Their products are primarily paid for by healthcare providers and insurance companies.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
The market prices BVS at a premium of +53.3% to the model's intrinsic valueIntrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation →. This reflects optimism about the company's revenue growing at 7.2% per year over four years and its consistent positive operating cash flow, which has been positive in 4 out of 5 years. Separately, the reverse DCFReverse DCF — Instead of asking "what is this stock worth?", asks "what growth rate is the current market price already assuming?"
Why it matters: It crystallizes the bull thesis as a single number you can argue with. If the market expects 40% growth for 10 years and you do not believe that, the stock is overvalued.
Reference: 10–15% = sustainable for strong companies · 20–25% = exceptional · 30%+ = historically very rare
Full explanation → implies the price is consistent with roughly 14.6% annual per-share cash-flow growth, significantly higher than the model's 9.2% growth assumption.
Three Scenarios, Weighted
| Scenario | IV | Upside from today's price | Weight |
|---|---|---|---|
| Conservative | $7.60 | -43.8% | 40% |
| Base | $8.97 | -33.7% | 35% |
| Optimistic | $10.59 | -21.7% | 25% |
| Weighted | $8.83 | -34.8% | 100% |
Reading the last column: it is the move from today's price to each value (IV ÷ price − 1). The headline "premium/discount to model IV" measures the same gap from the value's side (price ÷ IV − 1), so the two percentages differ in size and sign by construction — e.g. a price 8% above value is a value 7.4% below price.
Business Model & Valuation
How They Make Money
Free Cash Flow DCF Medium
Owner-earnings FCF DCF: positive free cash flow (operating cash flow − capex − stock-based comp) in a sector suited for cash-flow-based valuation. FCF negative in 2/5 years.
▾ Exactly how the $0.43 normalized FCF/share is computed
2025: 59.4M
2024: 24.5M
2023: 5.3M
Sum ÷ 3 = 29.7M average total FCF
÷ 68.9M current diluted shares = $0.43/share
We divide the multi-year total-FCF average by today's share count (not each year's own share count), so the buyback effect is captured once, via the current denominator.
Show advanced inputs
| Revenue Growth | 7.2% |
| Sector Default | 10.0% |
| Sector Default Source | Healthcare sector default |
| Best Estimate | 9.2% |
| Method | blend(30% revenue_cagr, 70% sector) |
| Growth Basis | total |
What this model does NOT do: this is a consolidated owner-earnings cash-flow model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Revenue has been growing at 7.2% per year over four years, from $431M to $568.1 million.
Geography & Markets
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)40.8NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (2 notes — click to expand/collapse)
Guardrail Notes (2)
- Latest FCF ($0.1B, net of stock-based compensation) is 2.6x net income ($0.0B) - using 3yr average FCF to reduce one-time inflation.
- Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
FINANCIALS
Financial Statements (5-year tables — click to expand)
From Bioventus Inc.'s SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | 568.1M | 22.7M | $0.33 |
| 2024 | 573.3M | -36.1M | $-0.56 |
| 2023 | 512.3M | -156.2M | $-2.49 |
| 2022 | 512.1M | -158.7M | $-2.59 |
| 2021 | 430.9M | 19.4M | $-0.15 |
Cash Flow (5yr)
| Year | Operating CF | CapEx | − SBC | Free Cash Flow |
|---|---|---|---|---|
| 2025 | 74.7M | 2.6M | 12.7M | 59.4M |
| 2024 | 38.8M | 1.0M | 13.3M | 24.5M |
| 2023 | 15.3M | 7.4M | 2.7M | 5.3M |
| 2022 | -13.5M | 1.5M | 17.6M | -32.6M |
| 2021 | 23.0M | 13.5M | 19.8M | -10.4M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: 74.7M − 2.6M − 12.7M (stock-based comp) = 59.4M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a trailing 3-year average, not this single year.
Balance Sheet
| Total Assets | 683.6M |
| Total Liabilities | 455.1M |
| Equity | 184.1M |
| Total Debt | 294.0M |
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.
The questions people ask about BVS
Is Bioventus Inc. (BVS) a good stock to buy?
Bioventus Inc. (BVS) looks expensive against its own cash flows: the price is about 53% above our $8.83 estimate. Whether it is a good buy depends on whether the company can grow faster than that price assumes, on its financial health, and on what insiders are doing. All three are on this page. This is educational research from SEC filings, not investment advice.
Is Bioventus Inc. (BVS) overvalued?
Yes, by our measure. Bioventus Inc. (BVS) trades at $13.53, about 53% above our estimate of $8.83 for what the business is worth. This is educational research from SEC filings, not investment advice.
What is BVS's intrinsic value?
Our model estimates BVS is worth about $8.83 per share, built from the cash the business is expected to generate, taken from its SEC filings. The market price is $13.53.
What growth is priced into BVS?
Working backwards from today's price, the market expects BVS's cash flow per share to grow by roughly 14.6% a year over the next five years. Compare that with the company's actual record on this page.
Where do these numbers come from?
From Bioventus Inc.'s own SEC filings (10-K and 10-Q), Form 4 insider filings and daily market prices. Every figure on the page links to how it was calculated, and the model's weak spots are listed next to its results.